GT Biopharma (GTBP) Payables (2010 - 2026)

GT Biopharma (GTBP) has reported Payables for 17 consecutive years, with $253000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Payables fell 89.37% year-over-year to $253000.0 in Q1 2026; TTM through Mar 2026 was $253000.0, a 89.37% decrease from a year earlier, with the FY2025 full-year figure at $748000.0, down 80.59% from the prior year.
• Payables was $253000.0 for Q1 2026 at GT Biopharma, down from $748000.0 in the prior quarter.
• Over five years, Payables peaked at $8.2 million in Q1 2022 and troughed at $253000.0 in Q1 2026.
• A 5-year average of $3.7 million and a median of $3.5 million in 2022 frame the typical range for Payables.
• Across the five-year window, Payables surged 215.43% in 2022 and sank 89.37% in 2026, its largest moves.
• Over 5 years, Payables stood at $3.2 million in 2022, then surged by 70.31% to $5.4 million in 2023, then decreased by 28.38% to $3.9 million in 2024, then tumbled by 80.59% to $748000.0 in 2025, then sank by 66.18% to $253000.0 in 2026.
• The last three Payables figures came in at $253000.0 (Q1 2026), $748000.0 (Q4 2025), and $913000.0 (Q3 2025), per Business Quant data.